Normal organ development and many disease processes, such as cancer and tissue damage, depend upon formation of new blood vessels. Our research seeks to identify novel factors regulating blood vessel growth. In this context we have examined the role of proteins that mediate communication between cells, called connexins. By increasing our understanding of the factors affecting blood vessel growth we learn how to create novel therapies to enhance the treatment of ischemic disease and cancer.
Thromboxane Receptor Signaling In Endothelial Cells
Funder
National Health and Medical Research Council
Funding Amount
$584,985.00
Summary
Normal organ development and many disease processes, such as cancer and ischemia, depend upon formation of new blood vessels. Our research seeks to identify novel factors regulating blood vessel growth. In this context we have examined the role of short lived lipid derivatives, called eicosanoids. By increasing our understanding of the factors affecting blood vessel growth we learn how to create novel therapies to enhance the treatment of ischemic disease and cancer.
Is Hypoxia Inducible Factor 2 The Trigger Of The Angiogenic Switch And A Driver Of Disease Progression In Myeloma?
Funder
National Health and Medical Research Council
Funding Amount
$605,096.00
Summary
Multiple myeloma (MM) is a fatal cancer of plasma cells (PC). PC migrate to the bone marrow, which compared with other organs is low in oxygen (hypoxic). In response to this hypoxia, the cancer cells turn on the expression of genes called hypoxia-inducible factors (HIF). HIFs activate the expression of genes that encourage blood vessel formation, which in turn stimulates greater tumour growth and disease progression. This proposal will investigate the role of HIFs in the progression of MM.
Transcriptional Complexes In Haematopoiesis And T-cell Leukemia
Funder
National Health and Medical Research Council
Funding Amount
$557,939.00
Summary
Childhood T-cell leukemias have a poor prognosis for recovery. We are determining, with atomic level precision, how the proteins LMO2 (also linked to prostate and other cancers) and Tal1, and their binding partners contribute to both normal blood cell development and T-cell leukemia. With this information we are developing reagents that can be used to disrupt disease-causing complexes, and which will lead towards the development of new, specific, therapeutics for leukemias and other cancers.
Receptor Tyrosine Kinase Function As Molecular Target In Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$415,788.00
Summary
As molecular cell biologist and protein chemist my motivation for research is to tackle metastatic cancer, one of the principle health burdens of the 21 century. Over the next five years I will lead R&D programs with national and international collaborators that will generate new diagnostic approaches and insights in basic and translational research. These will allow us to develop anti-cancer drugs, which target several of the mechanisms that are active in metastatic cancers.
Development Of Anti-CXCR2 Monoclonal Antibodies For Tumour Therapy
Funder
National Health and Medical Research Council
Funding Amount
$174,867.00
Summary
New therapies to treat cancers and inflammatory diseases are urgently required. Our aim is to develop a new treatment for cancer and inflammation, by blocking the chemokine receptor CXCR2 which is central to angiogenesis (blood vessel growth) and inflammation. We have produced a highly effective monoclonal antibody (mAb) inhibitor of CXCR2, that is suitable for preclinical and clinical development. The project aims to examine the efficacy of this mAb in mouse tumour models and inflammation.
Understanding The Molecular Pathways That Determine Response To Anti-angiogenic Therapy
Funder
National Health and Medical Research Council
Funding Amount
$209,539.00
Summary
Anti-angiogenesis is an important new approach to treat conditions such as cancer and eye disease. Our study is designed to understand the molecular pathways that lead to patients either being or developing resistance to these treatments. Using advanced cell and molecular biology techniques we will identify ways in which the blood vessels evade these therapies. Once identified these molecules will provide additional targets for developing therapeutics and diagnostics.